Retinoblastoma protein prevents staurosporine-induced cell death in a retinoblastoma-defective human glioma cell line

Pathobiology

Volumn 74, Issue 1, 2007, Pages 22-31

  Yamasaki, Fumiyuki ^a   Kajiwara, Yoshinori ^a   Hama, Seiji ^a   Murakami, Taro ^a   Hidaka, Toshikazu ^a   Saito, Taiichi ^a   Yoshioka, Hiroyuki ^b   Sugiyama, Kazuhiko ^a   Arita, Kazunori ^c   Kurisu, Kaoru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b National Hospital Organization   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cell cycle arrest; Genome instability; Multinucleation; Retinoblastoma; Staurosporine

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P16; PROTEIN P21; RETINOBLASTOMA PROTEIN; STAUROSPORINE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSFECTION; GLIOMA; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINOBLASTOMA;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; GENES, P16; GLIOMA; HUMANS; RETINOBLASTOMA PROTEIN; STAUROSPORINE; TRANSFECTION;

ADENOVIRIDAE;

EID: 34248329482     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101048     Document Type: Article

References (57)

1. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F: Staurosporine, a potent inhibitor of phospholipid/Ca 2+ -dependent protein kinase. Biochem Biophys Res Commun 1986;135:397-402.
2. Fujita-Yamaguchi Y, Kathuria S: Characterization of receptor tyrosine-specific protein kinases by the use of inhibitors. Staurosporine is a 100-times more potent inhibitor of insulin receptor than IGF-I receptor. Biochem Biophys Res Commun 1988;157:955-962.
3. Fallon RJ: Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes. Biochem Biophys Res Commun 1990;170:1191-1196.
4. Baltuch GH, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 1993;33:495-501.
5. Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K: Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst 2000;92:1999-2008.
6. Gescher A: Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 1998;31:721-728.
7. Lee SI, Brown MK, Eastman A: Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 1999;58:1713-1721.
8. Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM: Inhibition of CDKs as a therapeutic modality. Ann NY Acad Sci 2000;910:207-221.
9. Orr MS, Reinhold W, Yu L, Schreiber-Agus N, O'Connor PM: An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts. J Biol Chem 1998;273:3803-3807.
10. Nishi K, Schnier JB, Bradbury EM: The accumulation of cyclin-dependent kinase inhibitor p27kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest. Exp Cell Res 1998;243:222-231.
11. Qiao L, Koutsos M, Tsai LL, Kozoni V, Guzman J, Shiff SJ, Rigas B: Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells. Cancer Lett 1996;107:83-89.
12. Sedlak J, Hunakova L, Sulikova M, Chorvath B: Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells. Leuk Res 1997;21:449-458.
13. Abe K, Yoshida M, Usui T, Horinouchi S, Beppu T: Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 1991;192:122-127.
14. Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkiewicz Z: Different effects of staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res 1992;52:470-473.
15. Gadbois DM, Hamaguchi JR, Swank RA, Bradbury EM: Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem Biophys Res Commun 1992;184:80-85.
16. Yamasaki F, Hama S, Yoshioka H, Kajiwara Y, Yahara K, Sugiyama K, Heike Y, Arita K, Kurisu K: Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line. Cancer Chemother Pharmacol 2003;51:271-283.
17. Dannenberg JH, van Rossum A, Schuijff L, te Riele H: Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 2000;14:3051-3064.
18. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T: Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 2000;14:3037-3050.
19. Chen X, Lowe M, Keyomarsi K: UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999;18:5691-5702.
20. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH: RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res 1999;5:2596-2604.
21. Schnier JB, Nishi K, Goodrich DW, Bradbury EM: G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci USA 1996;93:5941-5946.
22. Chau BN, Borges HL, Chen TT, Masselli A, Hunton IC, Wang JY: Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat Cell Biol 2002;4:757-765.
23. Lentini L, Pipitone L, Di Leonardo A: Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia 2002;4:380-387.
24. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430:797-802.
25. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 1996;12:103-110.
26. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996;56:694-699.
27. Hama S, Heike Y, Naruse I, Takahashi M, Yoshioka H, Arita K, Kurisu K, Goldman CK, Curiel DT, Saijo N: Adenovirus-mediated p16 gene transfer prevents drug-induced cell death through G1 arrest in human glioma cells. Int J Cancer 1998;77:47-54.
28. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day 3rd RS, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-5807.
29. Kawada M, Uehara Y, Mizuno S, Yamori T, Tsuruo T: Up-regulation of p27Kip1 correlates inversely with anchorage-independent growth of human cancer cell lines. Jpn J Cancer Res 1998;89:110-115.
30. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY: Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-1399.
31. Hama S, Matsuura S, Tauchi H, Yamasaki F, Kajiwara Y, Arita K, Yoshioka H, Heike Y, Mandai K, Kurisu K: p16 Gene transfer increases cell killing with abnormal nucleation after ionising radiation in glioma cells. Br J Cancer 2003;89:1802-1811.
32. Doostzadeh-Cizeron J, Evans R, Yin S, Goodrich DW: Apoptosis induced by the nuclear death domain protein p84N5 is inhibited by association with Rb protein. Mol Biol Cell 1999;10:3251-3261.
33. Zheng L, Lee WH: The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001;264:2-18.
34. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991;67:293-302.
35. Bagchi S, Weinmann R, Raychaudhuri P: The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 1991;65:1063-1072.
36. Kaelin WG Jr, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, et al: Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 1992;70:351-364.
37. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992;358:259-261.
38. Johnson DG, Schwarz JK, Cress WD, Nevins JR: Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-352.
39. Flemington EK, Speck SH, Kaelin WG Jr: E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1993;90:6914-6918.
40. Avni D, Yang H, Martelli F, Hofmann F, El Shamy WM, Ganesan S, Scully R, Livingston DM: Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell 2003;12:735-746.
41. An B, Dou QP: Cleavage of retinoblastoma protein during apoptosis: an interleukin 1β-converting enzyme-like protease as candidate. Cancer Res 1996;56:438-442.
42. Janicke RU, Walker PA, Lin XY, Porter AG: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 1996;15:6969-6978.
43. Tan X, Wang JY: The caspase-RB connection in cell death. Trends Cell Biol 1998;8:116-120.
44. Fattman CL, Delach SM, Dou QP, Johnson DE: Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. Oncogene 2001;20:2918-2926.
45. Fattman CL, An B, Dou QP: Characterization of interior cleavage of retinoblastoma protein in apoptosis. J Cell Biochem 1997;67:399-408.
46. Zheng L, Lee WH: Retinoblastoma tumor suppressor and genome stability. Adv Cancer Res 2002;85:13-50.
47. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE, Eguia R, Dean DC, Esteller M, Jenuwein T, Blasco MA: Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol 2005;7:420-428.
48. Ruegg UT, Burgess GM: Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989;10:218-220.
49. Bossy-Wetzel E, Newmeyer DD, Green DR: Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 1998;17:37-49.
50. Zhou W, Lin Y, Wersto R, Chrest J, Gabrielson E: Staurosporine-induced G(1) arrest in cancer cells depends on an intact pRB but is independent of p16 status. Cancer Lett 2002;183:103-107.
51. Shekhar MP, Lyakhovich A, Visscher DW, Heng H, Kondrat N: Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Res 2002;62:2115-2124.
52. Rajagopalan H, Lengauer C: Aneuploidy and cancer. Nature 2004;432:338-341.
53. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R: Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 2004;101:4459-4464.
54. Jin J, Woodgett JR: Chronic activation of protein kinase Bβ/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis. Oncogene 2005;24:5459-5470.
55. Limoli CL, Hartmann A, Shephard L, Yang CR, Boothman DA, Bartholomew J, Morgan WF: Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. Cancer Res 1998;58:3712-3718.
56. Tsuiki H, Nitta M, Tada M, Inagaki M, Ushio Y, Saya H: Mechanism of hyperploid cell formation induced by microtubule inhibiting drug in glioma cell lines. Oncogene 2001;20:420-429.
57. Waldman T, Lengauer C, Kinzler KW, Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716.